Two new neolignans from the roots of Platycodon grandiflorus and their hypolipidemic effects

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2023-10-01 DOI:10.1016/j.phytol.2023.08.004

Huu Giap Tran , Mai Thao Vu , Van Hung Nguyen , Thi Minh Hien Hoang , Thi Hoai Thu Ngo , Thi Hoa Phan , Xuan Nhiem Nguyen , Thi Minh Hang Nguyen

{"title":"Two new neolignans from the roots of Platycodon grandiflorus and their hypolipidemic effects","authors":"Huu Giap Tran , Mai Thao Vu , Van Hung Nguyen , Thi Minh Hien Hoang , Thi Hoai Thu Ngo , Thi Hoa Phan , Xuan Nhiem Nguyen , Thi Minh Hang Nguyen","doi":"10.1016/j.phytol.2023.08.004","DOIUrl":null,"url":null,"abstract":"<div>Two new neolignans, plagraneolignans A-B (1-2), in addition to eight known compounds, platycodin D (3), platycodin J (4), platycodin D3 (5), platyconic acid A (6), platycoside E (7), chlorogenic acid (8), hexyl β-sophoroside (9) and tryptophan (10), were isolated from the roots of Platycodon grandiflorus. Their structures were elucidated by means of comprehensive spectroscopic analysis, including 1D, 2D and HRESIMS, as well as though comparison with published data. The antioxidant and hypolipidemic effects of all isolated compounds were evaluated. Compounds 1-2, 8 and 10 exhibited the DPPH radical scavenging activity with IC50 values ranging from 40.4 to 54.9 µM and the capacity of reducing intracellular lipid levels on the HepG2 cell line in the range of 21.79–32.40%.</div>","PeriodicalId":20408,"journal":{"name":"Phytochemistry Letters","volume":"57 ","pages":"Pages 167-171"},"PeriodicalIF":1.3000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytochemistry Letters","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1874390023001519","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 1

Abstract

Two new neolignans, plagraneolignans A-B (1-2), in addition to eight known compounds, platycodin D (3), platycodin J (4), platycodin D₃ (5), platyconic acid A (6), platycoside E (7), chlorogenic acid (8), hexyl β-sophoroside (9) and tryptophan (10), were isolated from the roots of Platycodon grandiflorus. Their structures were elucidated by means of comprehensive spectroscopic analysis, including 1D, 2D and HRESIMS, as well as though comparison with published data. The antioxidant and hypolipidemic effects of all isolated compounds were evaluated. Compounds 1-2, 8 and 10 exhibited the DPPH radical scavenging activity with IC₅₀ values ranging from 40.4 to 54.9 µM and the capacity of reducing intracellular lipid levels on the HepG2 cell line in the range of 21.79–32.40%.

Abstract Image

查看原文本刊更多论文

桔梗根中两种新木脂素及其降血脂作用

从桔梗(Platycodon tiflorus)的根中分离得到2个新木质素化合物:plataneolignans A- b(1-2)，以及8个已知化合物:桔梗素D(3)、桔梗素J(4)、桔梗素D3(5)、桔梗酸A(6)、桔梗素E(7)、绿原酸(8)、己基β-槐苷(9)和色氨酸(10)。通过综合光谱分析，包括1D, 2D和hremsims，以及与已发表数据的比较，阐明了它们的结构。评价了所有分离化合物的抗氧化和降血脂作用。化合物1-2、8和10具有清除DPPH自由基的活性，IC50值为40.4 ~ 54.9µM，降低HepG2细胞株细胞内脂质水平的能力为21.79 ~ 32.40%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.